MediWound Ltd MDWD Financial and Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $110

22:20 EST 3 Dec 2019 | BioPortfolio Report Blog

MediWound Ltd MDWD Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.

Corporate strategy Analyst's summarization of the company's business strategy.

SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history Progression of key events associated with the company.

Major products and services A list of major products, services and brands of the company.

Key competitors A list of key competitors to the company.

Key employees A list of the key executives of the company.

Executive biographies A brief summary of the executives' employment history.

Key operational heads A list of personnel heading key departments/functions.

Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


MediWound Ltd MediWound is a biopharmaceutical company that develops, manufactures and commercializes novel therapeutics to address the unmet needs in the areas of chronic, severe burns, other hardtoheal wounds and for connective tissue disorders. The company uses its patented proteolytic enzyme technology for the development of its products. The company offers NexoBrid, a drug for the removal of damaged or dead tissue, namely, eschar, in adults with severe burns deep partial and fullthickness thermal burns. EscharEX, pipeline drug candidate for the removal of damaged, dead or infected tissues from chronic wounds; MWPC003, a preclinical candidate for treating connective tissue Disorders. The company markets NexoBrid in the Europe, Israel through its own commercial organization and in Argentina, South Korea through its local distributors. MediWound is headquartered in Yavne, Israel.

MediWound Ltd Key Recent Developments

Jun 11,2019: MediWound appoints Mr. Boaz GurLavie as chief financial officer

May 21,2019: MediWound announces first quarter 2019 financial results

Mar 25,2019: MediWound announces fourth quarter and fiscal year 2018 financial results

Mar 12,2019: MediWound announces executive leadership changes

Oct 13,2018: MediWound announces third quarter 2018 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Original Article: MediWound Ltd MDWD Financial and Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $110


More From BioPortfolio on "MediWound Ltd MDWD Financial and Strategic SWOT Analysis Review [Published by Global Data] Prices from USD $110"

Quick Search

Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...